Skip to main content
. 2019 Dec 30;12(1):87. doi: 10.3390/cancers12010087

Figure 1.

Figure 1

Cytotoxicity effect was enhanced in magnolol combined with sorafenib as compared to alone treatment. Viable SK-Hep1 and Hep3B cells after sorafenib (0–20 µM) combined with or without magnolol (50 µM) or LY294002 (10 µM). Cells were assayed by MTT methods and quantified by excel software. The combination results were all normalized with alone treatment of magnolol (50 µM) or LY294002 (10 µM). Cytotoxicity results of magnolol combined sorafenib for (A) 24 h and (B) 48 h on SK-Hep1 cells; or on Hep3B cells for (C) 24 h and (D) 48 h. The quantification result of sorafenib combined with or without LY294002 (10 µM) for (E) 24 h and (F) 48 h on SK-Hep1 cells; or on Hep3B cells for (G) 24 h and (H) 48 h. Combination index of sorafenib combined with (I,J) magnolol or (K,L) LY294002 for 48 h on SK-Hep1 or Hep3B cells. (** p < 0.01 was compared with 0 µM sorafenib; # p < 0.05 and ## p < 0.01 were both compared with alone treatment).